Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 7:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 116 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: aspirin and clopidogrel Clear all
Completed Phase 2 Interventional Results available

Antiplatelet Therapy in HIV

NCT02559414
View directory record Official record
Conditions
HIV, Cardiovascular Diseases, Inflammation
Interventions
Aspirin, Clopidogrel
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years to 80 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2018 · Synced Sep 26, 2026, 7:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Aspirin and Thienopyridine Resistance in Peripheral Arterial Disease

NCT03174990
View directory record Official record
Conditions
Peripheral Arterial Disease, Clopidogrel, Poor Metabolism of
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2017 · Synced Sep 26, 2026, 7:03 PM EDT
Terminated Phase 3 Interventional

Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)

NCT00557921
View directory record Official record
Conditions
Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions
CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin
Drug
Lead sponsor
Cogentus Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
247
States / cities
Alexander City, Alabama • Birmingham, Alabama • Geneva, Alabama + 205 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2009 · Synced Sep 26, 2026, 7:03 PM EDT
Completed Not applicable Interventional

Study of Optimal Clopidogrel Duration in Patients Receiving Drug Eluting Stents (SCORE Trial)

NCT00781573
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Clopidogrel
Drug
Lead sponsor
North Texas Veterans Healthcare System
Federal
Eligibility
21 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Sep 26, 2026, 7:03 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders

NCT00642811
View directory record Official record
Conditions
Stable Coronary Artery Disease
Interventions
Ticagrelor, Clopidogrel, Aspirin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Jonesboro, Arkansas • Ormond Beach, Florida • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2011 · Synced Sep 26, 2026, 7:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

PACT (Platelet Activity After Clopidogrel Termination)

NCT00619073
View directory record Official record
Conditions
Blood Platelets, Clopidogrel
Interventions
clopidogrel + aspirin, placebo, Aspirin
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
21 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Sep 26, 2026, 7:03 PM EDT
Enrolling by invitation Phase 4 Interventional

Quality Improvement and Practice Based Research in Neurology Using the EMR

NCT02670161
View directory record Official record
Conditions
Brain Tumors, Epilepsy, Migraine, Mild Cognitive Impairment, Concussion, Multiple Sclerosis, Neuropathy, Parkinson's, Restless Legs Syndrome, Stroke
Interventions
Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 100 Years
Enrollment
3,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 23, 2025 · Synced Sep 26, 2026, 7:03 PM EDT
Completed Phase 4 Interventional Results available

The Dual Antiplatelet Therapy Study (DAPT Study)

NCT00977938
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Placebo & Aspirin, Clopidogrel & Aspirin, Prasugrel & Aspirin
Drug
Lead sponsor
Baim Institute for Clinical Research
Other
Eligibility
18 Years and older
Enrollment
25,682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
178
States / cities
Fairhope, Alabama • Gilbert, Arizona • Phoenix, Arizona + 143 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Sep 26, 2026, 7:03 PM EDT
Completed Phase 4 Interventional Results available

Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients

NCT01823510
View directory record Official record
Conditions
Type-2 Diabetes Mellitus, Coronary Artery Disease
Interventions
Ticagrelor + Aspirin, Clopidogrel + Aspirin
Drug
Lead sponsor
Juan J Badimon
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Sep 26, 2026, 7:03 PM EDT
Not listed Phase 4 Interventional

Study Comparing Treatment Effectiveness of Guideline Indicated APT for ACS in Patients With CKD

NCT03150667
View directory record Official record
Conditions
Chronic Kidney Diseases, Acute Coronary Syndrome
Interventions
Ticagrelor, Clopidogrel
Drug
Lead sponsor
North Texas Veterans Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Durham, North Carolina • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Sep 26, 2026, 7:03 PM EDT
Completed Phase 4 Interventional Results available

The Influence of Smoking Status on Prasugrel and Clopidogrel Treated Subjects Taking Aspirin and Having Stable Coronary Artery Disease

NCT01260584
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Prasugrel, Clopidogrel
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 74 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Baltimore, Maryland • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Sep 26, 2026, 7:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Targeting Platelets in Chronic HIV Infection

NCT02578706
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Clopidogrel, Aspirin, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Sep 26, 2026, 7:03 PM EDT
Completed Phase 3 Interventional Results available

PLATINUM Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions-Pharmacokinetics (PLATINUM PK)

NCT01510327
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PROMUS Element Everolimus-Eluting Coronary Stent System, Aspirin, Thienopyridine
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Loveland, Colorado • Petoskey, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Sep 26, 2026, 7:03 PM EDT
Recruiting Phase 3 Interventional

Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

NCT04045665
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Bleeding
Interventions
Antiplatelet-only strategy, Oral Anticoagulant plus background antiplatelet therapy
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
3,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
51
States / cities
Little Rock, Arkansas • Los Angeles, California • Stanford, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 26, 2026, 7:03 PM EDT
Completed No phase listed Observational

Patients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet Inhibition

NCT01582217
View directory record Official record
Conditions
Percutaneous Coronary Intervention, Dual Antiplatelet Therapy, Aspirin, Clopidogrel
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2015 · Synced Sep 26, 2026, 7:03 PM EDT
Completed Not applicable Interventional

The Effects of MAP and EtCO2 on Venous Sinus Pressures

NCT03867461
View directory record Official record
Conditions
Idiopathic Intracranial Hypertension
Interventions
Venous Sinus Stenting, Adjustment to end-tidal carbon dioxide concentrations ( 38-40 mmHg range), Adjustment to Mean Arterial Pressure (100-110 mmHg range), Adjustment to Mean Arterial Pressure (60-80 mmHg range), Adjustment to end-tidal carbon dioxide concentrations (24-26 mmHg range)
Procedure · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Sep 26, 2026, 7:03 PM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)

NCT00687076
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Ezetimibe, Niaspan, Statin therapy, Standard care, Aspirin, Clopidogrel, Placebo Niaspan, Placebo Ezetimibe, Percutaneous transluminal angioplasty (PTA)
Drug · Behavioral · Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
40 Years to 80 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Sep 26, 2026, 7:03 PM EDT
Completed Phase 4 Interventional Results available

Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus

NCT02548650
View directory record Official record
Conditions
Myocardial Infarction, Diabetes Mellitus, Peripheral Arterial Disease
Interventions
Vorapaxar, Clopidogrel, Aspirin
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Sep 26, 2026, 7:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Retinal Blood Flow and Microthrombi in Type 1 Diabetes

NCT00406991
View directory record Official record
Conditions
Diabetes, Diabetic Retinopathy
Interventions
aspirin, clopidogrel
Drug
Lead sponsor
Schepens Eye Research Institute
Other
Eligibility
18 Years to 45 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 29, 2015 · Synced Sep 26, 2026, 7:03 PM EDT
Recruiting Phase 4 Interventional

The Switching Antiplatelet-9 (SWAP-9) Study

NCT06588595
View directory record Official record
Conditions
Coronary Arterial Disease (CAD)
Interventions
Prasugrel/Ticagrelor monotherapy or aspirin plus clopidogrel, Aspirin plus clopidogrel
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 26, 2026, 7:03 PM EDT
Completed Phase 3 Interventional Results available

The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions

NCT00823212
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PROMUS Coronary Stent System, PROMUS Element Coronary Stent System, Aspirin, Thienopyridine
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
75
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Sep 26, 2026, 7:03 PM EDT
Completed Phase 2Phase 3 Interventional

Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence (FASTER)

NCT00109382
View directory record Official record
Conditions
Transient Ischemic Attack, Stroke
Interventions
Aspirin, Clopidogrel, Simvastatin
Drug
Lead sponsor
University of Calgary
Other
Eligibility
40 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2008 · Synced Sep 26, 2026, 7:03 PM EDT
Completed Phase 4 Interventional

Clopidogrel and Aspirin Together: The Effect on C-Reactive Protein Trial

NCT00343876
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
aspirin, clopidogrel
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 20, 2008 · Synced Sep 26, 2026, 7:03 PM EDT
Completed Phase 1 Interventional Results available

Early Use of Rosuvastatin in Acute Coronary Syndromes: Targeting Platelet-Leukocyte Interactions

NCT01241903
View directory record Official record
Conditions
Acute Coronary Syndrome, Angioplasty, Transluminal, Percutaneous Coronary, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Blood Platelets
Interventions
rosuvastatin, placebo
Drug
Lead sponsor
Susan Smyth
Other
Eligibility
18 Years to 80 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Sep 26, 2026, 7:03 PM EDT